Really? After 200% gains?!? Expect it to settle, first day it´s losing some steam. Good to see it rise steadily day by day during the last weeks, setback gonna be healthy right now.
Oppenheimer analyst Steven Lichtman maintained a Buy rating on Tandem Diabetes (NASDAQ: TNDM) today and set a price target of $24. The company’s shares closed yesterday at $20.31, close to its 52-week high of $21.50.
Market Data 
Markets 
AI
